Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 6 | 2025 | 68 | 1.240 |
Why?
|
| Sentinel Lymph Node | 3 | 2025 | 12 | 0.610 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2017 | 14 | 0.520 |
Why?
|
| Papanicolaou Test | 1 | 2016 | 46 | 0.470 |
Why?
|
| Vaginal Smears | 1 | 2016 | 59 | 0.470 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 150 | 0.430 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 170 | 0.410 |
Why?
|
| Gynecology | 1 | 2014 | 55 | 0.400 |
Why?
|
| Patient Simulation | 1 | 2014 | 67 | 0.400 |
Why?
|
| Self Efficacy | 1 | 2014 | 201 | 0.380 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 364 | 0.380 |
Why?
|
| Career Choice | 1 | 2014 | 132 | 0.370 |
Why?
|
| Ovarian Neoplasms | 3 | 2021 | 165 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 726 | 0.350 |
Why?
|
| Women's Health | 1 | 2014 | 374 | 0.340 |
Why?
|
| Students, Medical | 1 | 2014 | 265 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 369 | 0.270 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2025 | 22 | 0.270 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2025 | 39 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 91 | 0.200 |
Why?
|
| Leukocytosis | 2 | 2013 | 15 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2025 | 6811 | 0.190 |
Why?
|
| Uterine Artery Embolization | 1 | 2020 | 4 | 0.170 |
Why?
|
| Leiomyoma | 1 | 2020 | 18 | 0.160 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 36 | 0.160 |
Why?
|
| Female | 13 | 2025 | 33765 | 0.160 |
Why?
|
| Aged | 10 | 2025 | 14840 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 45 | 0.130 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 13 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 1 | 2016 | 18 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 406 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2017 | 100 | 0.120 |
Why?
|
| Middle Aged | 9 | 2025 | 18112 | 0.120 |
Why?
|
| Anastomotic Leak | 1 | 2016 | 36 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 640 | 0.120 |
Why?
|
| Rectum | 1 | 2016 | 96 | 0.120 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 539 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 315 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2017 | 224 | 0.110 |
Why?
|
| Humans | 13 | 2025 | 64778 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 304 | 0.100 |
Why?
|
| Manikins | 1 | 2014 | 21 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2021 | 5764 | 0.100 |
Why?
|
| Clinical Clerkship | 1 | 2014 | 91 | 0.100 |
Why?
|
| Lymphatic Metastasis | 2 | 2025 | 90 | 0.100 |
Why?
|
| Boston | 1 | 2014 | 257 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 23 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2013 | 15 | 0.100 |
Why?
|
| Prognosis | 3 | 2025 | 1773 | 0.090 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2014 | 158 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 99 | 0.090 |
Why?
|
| Biomarkers | 1 | 2017 | 1468 | 0.090 |
Why?
|
| Algorithms | 1 | 2016 | 1034 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2603 | 0.080 |
Why?
|
| Inflammation | 1 | 2017 | 1188 | 0.080 |
Why?
|
| Mass Screening | 1 | 2016 | 696 | 0.080 |
Why?
|
| Adult | 4 | 2025 | 17243 | 0.080 |
Why?
|
| Massachusetts | 1 | 2016 | 2137 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2016 | 1311 | 0.080 |
Why?
|
| Risk Factors | 2 | 2016 | 5399 | 0.070 |
Why?
|
| Hysterectomy | 2 | 2020 | 71 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2025 | 39 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2013 | 67 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 414 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 884 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2017 | 21 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2017 | 47 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1410 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 168 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 325 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 5565 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1002 | 0.030 |
Why?
|
| Death | 1 | 2013 | 33 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2012 | 103 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 217 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 655 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 847 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 3299 | 0.020 |
Why?
|
| United States | 1 | 2021 | 8051 | 0.020 |
Why?
|